Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey

被引：0
作者：
E Jantunen
T Wiklund
E Juvonen
M Putkonen
T Lehtinen
O Kuittinen
K Franssila
K-O Söderström
S Leppä
E Elonen
K Remes
T Nousiainen
机构：
[1] Kuopio University Hospital,Department of Medicine
[2] Helsinki University Central Hospital,Department of Oncology
[3] Helsinki University Central Hospital,Department of Medicine
[4] Turku University Central Hospital,Department of Medicine
[5] Tampere University Hospital,Department of Oncology
[6] Oulu University Hospital,Department of Oncology
[7] Medix Laboratories,Department of Pathology
[8] University of Turku,undefined
[9] Molecular Cancer Biology Research Program,undefined
[10] Haartman Institute,undefined
[11] University of Helsinki,undefined
来源：
Bone Marrow Transplantation | 2004年 / 33卷
关键词：
peripheral T-cell lymphoma; autologous stem cell transplantation; toxicity; outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Limited experience is available on the feasibility and efficacy of high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL). Therefore, a nation-wide survey was conducted in adult patients transplanted for PTCL in Finland during 1990–2001. After histopathology review, 37 patients were identified. The median age was 46 years (16–68) at the time of ASCT. Histology included PTCL not otherwise specified in 14 patients, anaplastic large cell lymphoma (ALCL) in 14 patients, and other in nine patients. Disease status at the time of ASCT was CR/PR1 in 18 patients; CR/PR2 in 14 patients, and other in five patients. HDT consisted of either BEAC (N=22) or BEAM (N=15), supported by blood stem cells in 34 patients (92%). Early transplant-related mortality was 11%. With a median follow-up of 24 months from HDT, 16 patients (43%) have relapsed or progressed. The estimated 5-year overall survival (OS) was 54%. Patients with ALCL had superior OS when compared with other subtypes (85 vs 35%, P=0.007). OS at 5 years was 63% in patients transplanted in CR/PR1 vs 45% in those transplanted in other disease status (P=NS). Prospective studies are needed to define the role of ASCT in this lymphoma type.
引用
收藏
页码：405 / 410
页数：5
相关论文
共 84 条
[1]  
Armitage J(1989)Clinical significance of immunophenotyping in diffuse aggressive non-Hodgkin's lymphoma J Clin Oncol 7 1783-1785
[2]  
Vose J(1990)Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with LNH-84 regimen Ann Oncol 1 45-50
[3]  
Linder J(1997)Evaluation of the revised European–American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma Blood 89 4514-4520
[4]  
Coiffier B(1998)Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphoma. Groupe d' Etudes des Lymphomes de l'Adulte (GELA) Blood 92 76-82
[5]  
Brousse N(1998)Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification Ann Oncol 9 849-855
[6]  
Peuchmauer M(1997)Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma J Clin Oncol 15 2296-2301
[7]  
Melnyk A(1998)New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic types. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol 16 2780-2795
[8]  
Rodriquez A(1996)Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/−radiotherapy) and autologous bone marrow transplantation Blood 87 1243-1248
[9]  
Pugh WC(1999)Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant 23 437-442
[10]  
Gisselbrecht C(2000)Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial Br J Haematol 109 736-742
123456789